Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease.
Wilson MK, Pujade-Lauraine E, Aoki D, Mirza MR, Lorusso D, Oza AM, du Bois A, Vergote I, Reuss A, Bacon M, Friedlander M, Gallardo-Rincon D, Joly F, Chang SJ, Ferrero AM, Edmondson RJ, Wimberger P, Maenpaa J, Gaffney D, Zang R, Okamoto A, Stuart G, Ochiai K; participants of the Fifth Ovarian Cancer Consensus Conference. Wilson MK, et al. Among authors: bacon m. Ann Oncol. 2017 Apr 1;28(4):727-732. doi: 10.1093/annonc/mdw663. Ann Oncol. 2017. PMID: 27993805 Free PMC article.
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours.
Leary AF, Quinn M, Fujiwara K, Coleman RL, Kohn E, Sugiyama T, Glasspool R, Ray-Coquard I, Colombo N, Bacon M, Zeimet A, Westermann A, Gomez-Garcia E, Provencher D, Welch S, Small W, Millan D, Okamoto A, Stuart G, Ochiai K; participants of the Fifth Ovarian Cancer Consensus Conference. Leary AF, et al. Among authors: bacon m. Ann Oncol. 2017 Apr 1;28(4):718-726. doi: 10.1093/annonc/mdw662. Ann Oncol. 2017. PMID: 27993794 Free PMC article.
Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors.
McGee J, Bookman M, Harter P, Marth C, McNeish I, Moore KN, Poveda A, Hilpert F, Hasegawa K, Bacon M, Gatsonis C, Brand A, Kridelka F, Berek J, Ottevanger N, Levy T, Silverberg S, Kim BG, Hirte H, Okamoto A, Stuart G, Ochiai K; participants of the 5th Ovarian Cancer Consensus Conference. McGee J, et al. Among authors: bacon m. Ann Oncol. 2017 Apr 1;28(4):702-710. doi: 10.1093/annonc/mdx010. Ann Oncol. 2017. PMID: 28119296 Free article.
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.
Karam A, Ledermann JA, Kim JW, Sehouli J, Lu K, Gourley C, Katsumata N, Burger RA, Nam BH, Bacon M, Ng C, Pfisterer J, Bekkers RLM, Casado Herráez A, Redondo A, Fujiwara H, Gleeson N, Rosengarten O, Scambia G, Zhu J, Okamoto A, Stuart G, Ochiai K; participants of the 5th Ovarian Cancer Consensus Conference. Karam A, et al. Among authors: bacon m. Ann Oncol. 2017 Apr 1;28(4):711-717. doi: 10.1093/annonc/mdx011. Ann Oncol. 2017. PMID: 28327917 Free article.
Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.
Bookman MA, Okamoto A, Stuart G, Yanaihara N, Aoki D, Bacon M, Fujiwara K, González-Martín A, Harter P, Kim JW, Ledermann J, Pujade-Lauraine E, Quinn M, Ochiai K; 5th Ovarian Cancer Consensus Conference. Bookman MA, et al. Among authors: bacon m. Ann Oncol. 2017 Nov 1;28(suppl_8):viii30-viii35. doi: 10.1093/annonc/mdx449. Ann Oncol. 2017. PMID: 29232472 Free PMC article. Review.
A phase 3 trial of bevacizumab in ovarian cancer.
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. Perren TJ, et al. N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799. N Engl J Med. 2011. PMID: 22204725 Free article. Clinical Trial.
Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.
Lee CK, Gurney H, Brown C, Sorio R, Donadello N, Tulunay G, Meier W, Bacon M, Maenpaa J, Petru E, Reed N, Gebski V, Pujade-Lauraine E, Lord S, Simes RJ, Friedlander M. Lee CK, et al. Among authors: bacon m. Br J Cancer. 2011 Jul 26;105(3):360-5. doi: 10.1038/bjc.2011.256. Epub 2011 Jul 12. Br J Cancer. 2011. PMID: 21750553 Free PMC article. Clinical Trial.
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer.
Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Mangioni C, Simonsen E, James K, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson R, Swenerton K, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lidvall B, Bacon M, Birt A, Andersen J, Zee B, Paul J, Pecorelli S, Baron B, McGuire W. Piccart MJ, et al. Among authors: bacon m. Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:144-8. doi: 10.1111/j.1525-1438.2003.13357.x. Int J Gynecol Cancer. 2003. PMID: 14656271 Clinical Trial.
208 results